Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis.

Diagnosis Epidemiology Gout Incidence Incident Urate

Journal

BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571

Informations de publication

Date de publication:
28 Aug 2021
Historique:
received: 06 04 2021
accepted: 21 05 2021
entrez: 28 8 2021
pubmed: 29 8 2021
medline: 29 8 2021
Statut: epublish

Résumé

Elevated serum urate (SU) concentration is the central risk factor for the development of gout. The aim of this study was to examine the incidence of gout in people with low and normal SU levels (< 7.00 mg/dL). Longitudinal cohort data from the Atherosclerosis Risk in Communities Study (ARIC), Coronary Artery Risk Development in Young Adults Study (CARDIA), and both the Original and Offspring cohorts of the Framingham Heart Study (FHS) were used to determine incident gout by baseline SU over 3, 5, 10, 12 and 15 year periods. A Cox proportional hazards model with covariables of age, gender, ethnicity, and cohort was calculated to report the hazard ratios (HR) for incident gout. The incidence of gout at 15 years for a baseline SU < 4.00 mg/dL was 0.59%, 4.00-4.49 mg/dL was 1.28%, 4.50-4.99 mg/dL was 0.86%, 5.00-5.49 mg/dL was 0.94%, 5.50-5.99 mg/dL was 1.52%, 6.00-6.49 mg/dL was 2.91%, 6.50-6.99 mg/dL was 3.2%, and > 7.00 mg/dL was 12.2%. In an adjusted Cox proportional hazards model, compared to the referent baseline SU < 4.00 mg/dL, there was a non-significant increase in incident gout for baseline SU bands between 4.00-5.49 mg/dL, whereas incident gout was significantly increased for SU 5.50-5.99 mg/dL (HR 2.60), 6.00-6.49 mg/dL (HR 3.70), 6.50-6.99 mg/dL (HR 5.24) and > 7.00 mg/dL (HR 18.62). A baseline SU of 5.50 mg/dL or more is a risk factor for development of gout over 15 years. However, incident gout does occur over time in a small proportion of people with lower baseline SU levels.

Identifiants

pubmed: 34452645
doi: 10.1186/s41927-021-00204-4
pii: 10.1186/s41927-021-00204-4
pmc: PMC8399746
doi:

Types de publication

Journal Article

Langues

eng

Pagination

33

Subventions

Organisme : NHLBI NIH HHS
ID : N01HC55020
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55018
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025005
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC48049
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL059367
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL086694
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55015
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC95095
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55016
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC48047
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC48048
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG004402
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55022
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC48050
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55019
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR072571
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55021
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL087641
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Arthritis Rheumatol. 2014 Jan;66(1):185-96
pubmed: 24449584
Arthritis Rheumatol. 2019 Jun;71(6):991-999
pubmed: 30618180
BMC Cardiovasc Disord. 2016 Dec 15;16(1):256
pubmed: 27978810
Maturitas. 2018 Dec;118:67-73
pubmed: 30415758
Clin Rheumatol. 2012 Feb;31(2):239-45
pubmed: 21761146
Arthritis Rheumatol. 2020 Jun;72(6):879-895
pubmed: 32390306
Expert Opin Pharmacother. 2015 Mar;16(4):533-46
pubmed: 25547991
Ann Rheum Dis. 2014 Dec;73(12):2101-6
pubmed: 24026676
Arthritis Res Ther. 2008;10(5):R116
pubmed: 18822120
PLoS One. 2012;7(6):e39321
pubmed: 22723994
Ann Rheum Dis. 2017 Nov;76(11):1870-1882
pubmed: 28866649
Am J Med. 1987 Mar;82(3):421-6
pubmed: 3826098
Nat Rev Rheumatol. 2016 Aug;12(8):486-96
pubmed: 27411906
Ann Rheum Dis. 2019 Nov;78(11):1592-1600
pubmed: 31501138
Arthritis Rheum. 2012 Jan;64(1):121-9
pubmed: 22031222
Arthritis Rheum. 1972 Mar-Apr;15(2):189-92
pubmed: 5027604
BMJ. 2018 Oct 10;363:k3951
pubmed: 30305269
Br Med J. 1973 Feb 24;1(5851):449-51
pubmed: 4689833
Arthritis Care Res (Hoboken). 2016 Dec;68(12):1894-1898
pubmed: 27014846
Arthritis Rheum. 2010 Apr;62(4):1069-76
pubmed: 20131266
Rheumatology (Oxford). 2020 Oct 1;59(10):3108-3109
pubmed: 32182366
Lancet. 2018 Oct 20;392(10156):1403-1412
pubmed: 30343856
Nat Rev Rheumatol. 2018 Jun;14(6):341-353
pubmed: 29740155
Ann Rheum Dis. 2018 Jul;77(7):1048-1052
pubmed: 29463518

Auteurs

Philip C Robinson (PC)

University of Queensland Faculty of Medicine, Herston, Herston, Queensland, Australia. philip.robinson@uq.edu.au.
Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia. philip.robinson@uq.edu.au.

Christopher Frampton (C)

Department of Medicine, University of Otago, Christchurch, New Zealand.

Amanda Phipps-Green (A)

Department of Biochemistry, University of Otago, Dunedin, New Zealand.

Tuhina Neogi (T)

Department of Medicine, Boston University School of Medicine, Boston, USA.

Lisa Stamp (L)

Department of Medicine, University of Otago, Christchurch, New Zealand.

William Taylor (W)

Department of Medicine, University of Otago, Wellington, New Zealand.

Tony R Merriman (TR)

Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, USA.

Nicola Dalbeth (N)

Department of Medicine, University of Auckland, Auckland, New Zealand.

Classifications MeSH